Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
Proposed Mandatory Model | NPRM Comment Deadline: February 23, 2026 | Performance Period: January 1, 2027 – December 31, 2031
GUARD is not an incremental tweak to the Part D inflation rebate program — it is a structural reengineering of the rebate benchmark itself. The existing Medicare Part D Drug Inflation Rebate Program uses a domestic baseline price pegged to 2021 drug costs, escalated by CPI-U. GUARD would replace that domestic anchor entirely with an international reference price (IRP) benchmark, calculated from manufacturer-reported pricing data or CMS-observed pricing in countries meeting GDP per capita and minimum real economy size thresholds. The operational consequence: rebate liability is no longer tied to what a drug costs in the U.S. historically — it is tied to what comparable wealthy nations currently pay.
This is a significant design choice with major strategic implications. The source benchmark determines the magnitude of rebate obligations, and international prices for branded drugs are routinely 40–70% lower than U.S. list prices. Part D gross drug spending grew from $121 billion in 2014 to $276 billion in 2023 — nearly a 10% compound annual growth rate. Part D now represents approximately 30% of total U.S. gross drug spending. Any benchmark that compresses net prices toward international levels at even a fraction of that spending base produces enormous rebate flows. If the IRP benchmark closes even 20% of the price gap on qualifying drugs, the Trust Fund recapture over a five-year performance period could run into the tens of billions of dollars.
Three design features deserve close attention from strategic planners:
1. 25% Geographic Sample as a Legal Firewall. CMS proposes implementing GUARD only in randomly selected geographic areas covering 25% of Part D enrollees. This is not a coverage limitation — it is a litigation insulation strategy. By structuring GUARD as a randomized controlled model under Section 1115A authority, CMS establishes a test-versus-control framework that defends against industry challenges that the model exceeds CMMI's statutory authority. The Dobson-DaVanzo era legal challenges to mandatory models (MFN Drug Pricing Model, CJR) establish the template. CMS is front-running that challenge by leaning into the randomized design that most closely mirrors a legitimate "test."
2. Sole-Source Drug Targeting. GUARD restricts the rebate modification to sole-source drugs and sole-source biologics within 17 specified therapeutic categories, including antineoplastics, cardiovascular agents, immunological agents, blood glucose regulators, and antivirals. Sole-source designation eliminates the competition-based pricing constraint that CMS uses to exclude multi-source drugs. This is where U.S.-to-international price gaps are widest, and this is where GUARD's financial impact is concentrated. Manufacturers with large sole-source Part D portfolios — particularly in oncology, immunology, and metabolic disease — face the highest rebate exposure.
3. Mandatory Participation with No Opt-Out. Manufacturers do not choose to participate in GUARD. Any manufacturer whose sole-source Part D drug exceeds the international benchmark in covered geographic areas is subject to rebate invoicing. This eliminates the adverse selection problem that plagued voluntary CMMI models and represents CMS exercising the full coercive capacity of its Section 1115A authority.
GUARD has no direct financial mechanics for providers, ACOs, or health systems — manufacturer rebates flow directly to the Medicare Supplementary Medical Insurance (SMI) Trust Fund, not to participants in the clinical delivery system. There is no shared savings pool, no quality bonus, no benchmark reconciliation for providers.
However, the downstream financial implications for payers and plans are material:
Medicare Part D Plan Impact. Part D plans in covered geographic areas will experience reduced gross drug spending as the international benchmark compresses net costs to Medicare. If Part D plans' risk corridors and reinsurance structures adjust to reflect lower net costs, plan bids in covered areas could decrease, which would translate into lower beneficiary premiums. The competitive implication: Part D plans operating in GUARD-covered regions may hold a premium pricing advantage over plans in non-GUARD areas during the 2027–2031 period, assuming actuaries price the savings into bids.
Manufacturer Cash Flow Exposure. Rebate invoicing will run through the model period with reconciliation extending into 2033. Manufacturers with sole-source drugs in the 17 therapeutic categories should model their rebate exposure under three scenarios:
Who Is Disadvantaged: Pharmaceutical manufacturers with large sole-source Part D drug portfolios — particularly in oncology, immunology, rare disease, and metabolic disease — bear the entire financial burden. These are the same companies with the highest U.S.-to-international price spreads and the largest Part D revenue bases. Biologic manufacturers face compounded exposure because biosimilar competition exclusions make sole-source designation persistent.
Who Is Advantaged:
Interaction With Existing Programs: GUARD does not qualify as an Advanced APM or MIPS APM — providers earn no QPP credit for patient populations in GUARD-covered areas. GUARD also does not directly modify the IRA's Medicare Drug Price Negotiation Program (MDPNP) mechanics, but the two programs overlap in target drug categories (antineoplastics, immunologics, cardiovascular). A drug subject to both MDPNP negotiated pricing and GUARD's IRP rebate benchmark creates a dual compliance obligation whose net effect manufacturers will need to model carefully — the interaction of these two pricing authorities is not addressed in the current NPRM.
Physician Perspective Physicians practicing in the 17 covered therapeutic categories will not experience any direct payment change under GUARD. The clinical concern is formulary stability: if manufacturers respond to rebate pressure by restricting access, withdrawing drugs from Part D formularies, or restructuring patient assistance programs, prescribing physicians in GUARD-covered geographies may face formulary gaps for high-cost sole-source drugs. Monitor formulary change notifications in GUARD geographic areas beginning in late 2026.
Health System Perspective GUARD operates exclusively in Part D — outpatient pharmacy benefit — and does not touch Part B drug reimbursement or hospital drug acquisition costs. Health systems with 340B programs, specialty pharmacy operations, or infusion centers that capture Part D-billed drugs should model whether GUARD's rebate pressure alters manufacturer 340B compliance obligations or specialty pharmacy economics in covered markets.
Hospital Perspective Hospitals are not participants and face no direct financial exposure. The secondary effect to watch: if GUARD successfully reduces Part D cost-sharing burdens for beneficiaries, medication adherence may improve, reducing avoidable hospitalizations and ED utilization attributable to cost-driven non-adherence. The model's own rationale cites this pathway explicitly — CMS anticipates that financial strain from drug costs drives "greater severity of conditions and higher-cost care episodes including emergency care and hospitalization."
Payer/MA Plan Perspective This is where GUARD's strategic implications are most underappreciated. Medicare Advantage plans with integrated Part D (MAPD) operating in GUARD-covered geographies should model whether GUARD's IRP rebate mechanism reduces their own drug cost exposure or whether the mechanism flows exclusively through the SMI Trust Fund, bypassing MAPD plan economics entirely. Given that rebates under GUARD go directly to the Trust Fund — not back to plans — MAPD plans may see limited direct financial benefit even in covered geographies. The competitive dynamic favoring standalone Part D plans over MAPD plans in bid calculations is a technical issue worth raising in the NPRM comment period.
GUARD is a manufacturer-facing mandatory rebate model with no direct provider participation mechanism. Its strategic importance lies not in what it does to care delivery, but in what it signals: the Trump CMS — through CMMI Director Abe Sutton's shop — is willing to use Section 1115A authority aggressively to compress Part D drug spending through international reference pricing, a mechanism previously associated with the Biden era's abandoned Most Favored Nation model but now repackaged with tighter legal architecture and a randomized geographic design. Organizations with operational exposure to sole-source Part D drugs across any of the 17 therapeutic categories — whether as manufacturers, Part D plan sponsors, or specialty pharmacy operators — should submit NPRM comments before February 23, 2026 and begin scenario modeling now.